354 related articles for article (PubMed ID: 21204588)
21. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
[TBL] [Abstract][Full Text] [Related]
22. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
23. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
24. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
[TBL] [Abstract][Full Text] [Related]
25. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
26. Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis.
Jones AR; Enticott J; Ebeling PR; Mishra GD; Teede HT; Vincent AJ
Hum Reprod; 2024 May; 39(5):1013-1022. PubMed ID: 38396142
[TBL] [Abstract][Full Text] [Related]
27. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.
Wade SW; Curtis JR; Yu J; White J; Stolshek BS; Merinar C; Balasubramanian A; Kallich JD; Adams JL; Viswanathan HN
Bone; 2012 Apr; 50(4):870-5. PubMed ID: 22245467
[TBL] [Abstract][Full Text] [Related]
28. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
[TBL] [Abstract][Full Text] [Related]
29. Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life.
Obi EN; Swindle JP; Turner SJ; Russo PA; Altan A
J Manag Care Spec Pharm; 2016 Dec; 22(12):1446-1456. PubMed ID: 27882835
[TBL] [Abstract][Full Text] [Related]
30. The cost of treating osteoporosis in a managed health care organization.
Desai SS; Duncan BS; Sloan AS
J Manag Care Pharm; 2003; 9(2):142-9. PubMed ID: 14613343
[TBL] [Abstract][Full Text] [Related]
31. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
Xu Y; Viswanathan HN; Ward MA; Clay B; Adams JL; Stolshek BS; Kallich JD; Fine S; Saag KG
J Eval Clin Pract; 2013 Feb; 19(1):50-9. PubMed ID: 21914091
[TBL] [Abstract][Full Text] [Related]
32. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
33. Economic burden of osteoporotic fractures in US managed care enrollees.
Williams SA; Chastek B; Sundquist K; Barrera-Sierra S; Leader D; Weiss RJ; Wang Y; Curtis JR
Am J Manag Care; 2020 May; 26(5):e142-e149. PubMed ID: 32436682
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
35. Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.
King AB; Saag KG; Burge RT; Pisu M; Goel N
Osteoporos Int; 2005 Dec; 16(12):1545-57. PubMed ID: 15942702
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men.
Mikyas Y; Agodoa I; Yurgin N
Appl Health Econ Health Policy; 2014 Jun; 12(3):267-77. PubMed ID: 24477429
[TBL] [Abstract][Full Text] [Related]
37. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
38. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
[TBL] [Abstract][Full Text] [Related]
39. Effect of improved medication adherence on health care costs in osteoporosis patients.
Cho H; Byun JH; Song I; Kim HY; Ha YC; Kim TY; Lee YK; Jang S
Medicine (Baltimore); 2018 Jul; 97(30):e11470. PubMed ID: 30045269
[TBL] [Abstract][Full Text] [Related]
40. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
